Commencing Colorectal Cancer Screening at Age 45 Years in U.S. Racial Groups
Overview
Authors
Affiliations
Screening for colorectal cancer (CRC) is cost-effective for reducing its mortality among the average-risk population. In the US, CRC incidence and mortality differ among racial/ethnic groups, with non-Hispanic Blacks (NHB) and American Indian/Alaska Natives showing highest incidence and mortality and earlier presentation. Since 2005, some professional societies have recommended CRC screening for NHB to commence at 45 years or earlier; this was not implemented due to lack of recommendation from key groups that influence insurance payment coverage. In 2017 the highly influential U.S. Multi-Society Task Force for Colorectal Cancer recommended screening to commence at 45 years for NHB; this recommendation was supplanted by data showing an increase in early-onset CRCs in non-Hispanic Whites approaching the under-50-year rates observed for NHB. Subsequently the American Cancer Society and the USPSTF recommended that the entire average-risk population move to commence CRC screening at 45 years. Implementing screening in 45-49-year-olds has its challenges as younger groups compared with older groups participate less in preventive care. The US had made extensive progress pre-COVID-19 in closing the disparity gap for CRC screening in NHB above age 50 years; implementing screening at younger ages will take ingenuity, foresight, and creative strategy to reach a broader-aged population while preventing widening the screening disparity gap. Approaches such as navigation for non-invasive and minimally invasive CRC screening tests, removal of financial barriers such as co-pays, and complete follow up to abnormal non-invasive screening tests will need to become the norm for broad implementation and success across all racial/ethnic groups.
Brim H, Reddy C, Chirumamilla L, Oskrochi G, Deverapalli M, Rashid R Dig Dis Sci. 2024; 70(1):168-176.
PMID: 39586927 DOI: 10.1007/s10620-024-08739-5.
THE JEREMIAH METZGER LECTURE: ENVIRONMENTAL INFLUENCES ON COLORECTAL CANCER.
Carethers J Trans Am Clin Climatol Assoc. 2024; 134:181-199.
PMID: 39135583 PMC: 11316861.
Ali H, Ishtiaq R, Tedder B, Zweigle J, Nomigolzar R, Dahiya D JGH Open. 2024; 8(4):e13064.
PMID: 38623490 PMC: 11017855. DOI: 10.1002/jgh3.13064.
Improving Noninvasive Colorectal Cancer Screening.
Carethers J N Engl J Med. 2024; 390(11):1045-1046.
PMID: 38477992 PMC: 11016370. DOI: 10.1056/NEJMe2400366.